Abstract
Exaggerated responses to inhaled irritant chemicals are a hallmark of human airway diseases such as asthma. While the inflammatory processes and structural remodeling caused by respiratory irritants have received considerable attention, the mechanisms responsible for triggering acute episodes of irritant-induced airflow obstruction remain poorly understood. The non-selective cation channel Transient Receptor Potential Ankyrin 1 (TRPA1) has emerged as a promising target for therapeutic intervention in respiratory disorders as result of its unique biology that allows it to serve as the primary neuronal sensor not only for many of the hazardous irritants that cause chronic respiratory disease, but also for multiple inflammatory and oxidant mediators triggered by irritant exposure. Herein, we survey current evidence regarding TRPA1’s role as a sensor of an exceptionally wide array of oxidants, inflammatory mediators and hazardous air pollutants. Further, we review studies demonstrating that pharmacological inhibition or genetic disruption of TRPA1 protects laboratory animals from irritant-triggered expulsion/dilution reflexes. Lastly, we conclude with a comprehensive overview of patented TRPA1 antagonists and highlight recent progress made toward the goal of developing TRPA1-targeted therapeutics.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
